Drug Price Trends for DIMETANE

Average Pharmacy Cost for DIMETANE

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
DIMETANE 25 MG SOFTGEL	57237-0367-01	0.05574	EACH	2026-07-22
DIMETANE 25 MG SOFTGEL	57237-0367-99	0.05574	EACH	2026-07-22
DIMETANE 50 MG SOFTGEL	57237-0368-01	0.03073	EACH	2026-07-22
DIMETANE 50 MG SOFTGEL	57237-0368-99	0.03073	EACH	2026-07-22

DIMETANE market analysis, pricing outlook, and generic/biosimilar risk

Last updated: May 23, 2026

Market data, FDA status, label details, and competitive/IP landscape are not available in the prompt. Without those inputs, any price projection would be speculative and not decision-grade.

Key barriers to a credible forecast

• Lack of confirmation of the active ingredient(s) in “DIMETANE” (brand-to-API mapping is required to locate FDA listings, Orange Book entries, and comparable pricing).
• Missing country and formulation details (pricing is jurisdiction- and dosage-form specific).
• No FDA regulatory status (approved indications, route, strength, NDCs) to tie to utilization, reimbursement, and competition timing.
• No patent estate or litigation record to model exclusivity and generic entry risk.

Key Takeaways

• No decision-grade market analysis or price projections can be produced for “DIMETANE” from the provided information.
• A valid forecast requires the drug’s API, formulation, geography, and FDA/Orange Book status.

FAQs

1. What is the active ingredient behind “DIMETANE” and which NDCs does it map to?
2. What is the FDA approval status and current labeled indications for DIMETANE?
3. What does the Orange Book list for DIMETANE (patents, exclusivity, expiration dates)?
4. When are the earliest plausible generic or biosimilar entry windows for DIMETANE by jurisdiction?
5. What pricing benchmarks (wholesale acquisition cost, net price, reimbursement) exist for DIMETANE and close substitutes?